Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 11766343

[Interferon-alpha therapy].

A Tojo
View original source ↗Export metadata ↓

Abstract

Interferon-alpha (IFN alpha) with or without Ara-C is a choice of therapy for patients with CML who cannot receive allogeneic stem cell transplantation and gives those better prognosis than a conventional chemotherapy, although it has a variety of adverse effects. Especially, in a certain population(about 20%) of CML patients, IFN alpha can induce complete cytogenetic response in spite of persistant minimal residual disease. The basis of IFN alpha activity against CML is still unknown, but the contribution of immune-mediated mechanism is expected.

Explore related subjects

Antimetabolites, AntineoplasticAntineoplastic AgentsCytarabineHumansInterferon-alphaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveEnglish AbstractJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Tojo. 2001. [Interferon-alpha therapy].. https://pubmed.ncbi.nlm.nih.gov/11766343/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.

Adequate intracellular concentrations of ara-CMP, the monophosphorylated derivative of ara-C, are essential for its cytotoxicity. The critical step for ara-CMP formation is intracellular phosphorylation of ara-C by deoxycytidine kinase (dCK). A common nucleoside resistance mechanism is mutation affecting the expression or the specificity of dCK. We describe the ability of a tert-butyl S-acyl-thioethyl (SATE) derivative of ara-CMP (UA911) to circumvent ara-C resistance in a dCK-deficient human follicular lymphoma cell line (RL-G). The RL-G cell line was produced by continuous exposure to gemcitabine and displayed low dCK mRNA and protein expression that conferred resistance both to ara-C (2,250-fold) and to gemcitabine (2,092-fold). RL-G cells were able to take up the UA911 pronucleotide by diffusion and metabolize it to the corresponding ara-CMP and ara-CTP nucleotides, exhibiting a 199-fold reduction in resistance ratios, and a similar cell cycle arrest to the parental RL-7 cells. Exposures to 10, 50 or 100 microM concentrations of UA911 produced 160 +/- 7, 269 +/- 8 and 318 +/- 62 pmol ara-CTP/mg protein in RL-7 cells, and 100 +/- 12, 168 +/- 10 and 217 +/- 39 pmol ara-CTP/mg protein in RL-G cells, respectively. Exposure of RL-G cells to underivatized, radiolabeled ara-C produced no detectable amounts of the active triphosphate metabolites. We conclude that the UA911 pronucleotide is capable of overcoming dCK-mediated resistance. This result can be attributed to the unique cellular metabolism of the SATE pronucleotides giving rise to the intracellular delivery of ara-CMP to dCK-deficient cells.

Antimetabolites, Antineoplastic↗
PubMed2003

Enhancement of cytotoxic effect of bleomycin with transient permeabilization of plasma membrane by laser-induced multiple stress waves in vitro.

We investigated the effect of multiple stress waves with peak stress of less than 3 MPa on chemosensitivity of HeLa cells adhered on plastic. HeLa cells exposed to stress waves retained more than 95% of the viability found in untreated cells. The scanning electron microscopy of cells exposed to stress waves showed ruffling microvilli, indicating a change in the cell surface morphology. The cytotoxicity of bleomycin (BLM) on HeLa cells was enhanced by the stress waves exposure. Our findings demonstrated that the low-intensity stress wave would allow to deliver the BLM molecules into cytoplasm by repetition exposure.

Antimetabolites, Antineoplastic↗